WuXi XDC Cayman Inc (02268.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 77.70

From 52W high−9.52%

Volume5.66M

Market capHKD 93.61B

P/E (TTM)54.0x

P/S (TTM)11.6x

Div yield—

Key dataSep 18, 2026

Open

HKD 77.70

From 52W high

−9.52%

Volume

5.66M

Market cap

HKD 93.61B

ValuationView details →

P/E (Fwd)

21.6x

EV/EBITDA

35.6x

P/E (TTM)

54.0x

RSI (14)

63.3

MomentumView details →

1D Return

+0.65%

YTD Return

+26.75%

ValuationView details →

P/E (Fwd)

21.6x

P/E (TTM)

54.0x

EV/EBITDA

35.6x

EV/Sales

10.9x

P/S (TTM)

11.6x

P/B (TTM)

7.1x

ProfitabilityView details →

Gross Margin

36.50%

Net Margin

22.36%

EBITDA Margin

30.58%

ROE (TTM)

13.65%

ROA (TTM)

9.93%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+35.49%

EPS YoY

+22.00%

FCF YoY

+730.80%

Revenue CAGR 3Y

+81.73%

EPS CAGR 3Y

+110.93%

EBITDA YoY

+48.13%

MomentumView details →

1D Return

+0.65%

YTD Return

+26.75%

1Y Return

+9.38%

RSI (14)

63.3

vs 50D SMA

+18.32%

vs 200D SMA

+25.22%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

2.37x

Quick Ratio

2.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.59

EPS Surprise

−13.03%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.78

Avg Surprise (4Q)

−13.03%

Rev Surprise

−13.61%

Financials snapshotView financials →

Revenue (TTM)

11.98B

Net Income (TTM)

2.87B

Op. CF (TTM)

2.76B

Next earningsMar 29, 2027 →

Latest newsMore news →

WuXi XDC out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics for development of an ADC candidate against a single target, with upfront, milestone and royalty payments.3d ago

WuXi AppTec sold 53.524 million shares of WuXi XDC via block trades for about HK$3.92 billion, expecting an impact of about 3.143 billion yuan on 2026 pre-tax profit.24d ago

Similar companies

Access Bio, Inc.950130.KQ Danaher CorporationDHR Natera, Inc.NTRA Agilent Technologies, Inc.A IQVIA Holdings Inc.IQV Waters CorporationWAT Find similar companies →

Latest newsMore news →

WuXi XDC out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics for development of an ADC candidate against a single target, with upfront, milestone and royalty payments.3d ago WuXi AppTec sold 53.524 million shares of WuXi XDC via block trades for about HK$3.92 billion, expecting an impact of about 3.143 billion yuan on 2026 pre-tax profit.24d ago